铁疗法在心力衰竭中的作用:印度的一项共识声明
H K Chopra1, G S Wander2, Tiny Nair3
1Senior Consultant, Department of Cardiology, Medanta Moolchand Heart Institute, Delhi.
The Journal of the Association of Physicians of India
|June 24, 2023
概括
缺铁 (ID) 在心力衰竭 (HF) 患者中很常见,并且与更糟糕的结果有关. 静脉注射铁性碳酸盐糖 (FCM) 是一种新的治疗选择,用于治疗HF的ID,改善患者的健康和生活质量.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
背景情况:
- 缺铁 (ID) 在心力衰竭 (HF) 患者中很普遍,影响急性HF (AHF) 和慢性HF (CHF).
- 未经纠正的ID与HF患者的住院率和死亡率的增加有关.
- 慢性心力衰竭 (CHF) 中,ID正成为一种显著的并发症和治疗目标.
研究的目的:
- 提供专家的共识,诊断HF患者的ID.
- 概述适用于静脉注射铁碳素马尔托 (FCM) 治疗的患者个人资料.
- 为了指导IV FCM在HF患者的使用和监测.
主要方法:
- 基于共识的建议. 基于共识的建议.
- 专家意见综合. 专家意见综合.
- 对高频率IVFCM的临床证据的审查.
主要成果:
- 静脉注射铁性碳酸 (FCM) 有效地降低了与HF恶化相关的住院风险.
- 在HF患者中,FCM治疗导致功能能力的改善.
- 患者报告的生活质量 (QOL) 通过FCM疗法得到改善.
结论:
- 鉴定是HF中一个关键的,可治疗的并发症.
- IV FCM对于某些患有ID的HF患者来说是一个有价值的治疗选择.
- 建议在HF中使用标准化的ID诊断和治疗方案.
相关概念视频
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
Heart Failure VII: Nursing Interventions
111
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
111
Heart Failure Drugs: Inotropic Agents
640
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
640
Heart Failure Drugs: β-Blockers
371
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
371


